Search

Search Results

• 

  PO11 | THROMBOEMBOLIC EVENTS DURING PERIOPERATIVE THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE PANCREATIC CANCER IN THE PREOPANC-2 TRIAL R.A.L. Willems^1|5, A.E. Van Diepen^1|2|6, EN. Dekker⁷, Q.P. Janssen⁷, J.L. Van Dam⁷, N. Michiels⁸, C.W.F. Van Eijck⁹, K.E.P.E. Hermans^1|2, B.A. Bonsing⁸, K.P. Bosscha¹⁰, S.A.W. Bouwense^11|12, O. R. Busch^13|14, H. Ten Cate^4|5|15|16, P.P.L.O. Coene¹⁷, C.H.J. Van Eijck⁷, N. Van Es^18|19, E. Van Der Harst¹⁷, I.H.J.T. De Hingh²⁰, T.M. Karsten²¹, G. Kazemier^13|14, M.B. Van Der Kolk²², B. De Laat^3|5, M.S.L. Liem²², J.S.D. Mieog⁸, V.B. Nieuwenhuijs²⁴, G.A. Patijn²⁴, M. Roest³, H.C. Van Santvoort²⁵, L. Valkenburg-Van Iersel^1|2, R. F. De Wilde⁷, F. Wit²⁶, B.M. Zonderhuis^13|14, M.G. Besselink^13|14, M.Y.V. Homs⁶, G. Van Tienhoven^14|27, J. W. Wilmink^14|28, B. Groot Koerkamp⁷, J. De Vos-Geelen^1|2 | ¹Maastricht University Medical Center, Department of Internal Medicine, Division of Medical Oncology; ²GROW – Research Institute for Oncology & Reproduction, Maastricht University, Maastricht; ³Synapse Research Institute, Department of Functional Coagulation, Maastricht; ⁴Maastricht University Medical Center, Thrombosis Expert Center Maastricht, Maastricht; ⁵Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht; ⁶Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam; ⁷Erasmus MC Cancer Institute Rotterdam, University Medical Center Rotterdam, Department of Surgery; ⁸Leiden University Medical Center, Department of Surgery, Leiden; ⁹Solid Tumour Immunology Research Rotterdam (STIRR), Department of Pulmonary Medicine, Erasmus University Medical Centre, Rotterdam; ¹⁰Jeroen Bosch Hospital, Department of Surgery, Den Bosch; ¹¹Maastricht University Medical Center, Department of Surgery, Maastricht; ¹²Maastricht University Medical Center, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht; ¹³Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam; ¹⁴Cancer Center Amsterdam; ¹⁵Maastricht University Medical Center, Department of Internal Medicine, Division Vascular Medicine, Maastricht; ¹⁶Maastricht University, Department of Biochemistry, Laboratory for Clinical Thrombosis and Hemostasis, Maastricht; ¹⁷Maasstad Hospital, Department of Surgery, Rotterdam; ¹⁸Amsterdam UMC, location University of Amsterdam, Department of Vascular Medicine, Amsterdam; ¹⁹Amsterdam UMC, location University of Amsterdam, Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam; ²⁰Catharina Hospital, Department of Surgery, Eindhoven; ²¹OLVG, Department of Surgery, Amsterdam; ²²Radboud University Medical Center, Department of Surgery, Nijmegen; ²³Medisch Spectrum Twente, Department of Surgery, Enschede; ²⁴Isala Oncology Center, Department of Surgery, Zwolle; ²⁵Regional Academic Cancer Center Utrecht, St. Antonius Hospital and University Medical Center Utrecht, Department of Surgery, Utrecht; ²⁶Frisius MC, location Leeuwarden, Department of Surgery, Leeuwarden; ²⁷Amsterdam UMC, location University of Amsterdam, Department of Radiation Oncology, Amsterdam; ²⁸Amsterdam UMC, location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.507

  109

  PDF: 25
• 

  PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE T. Van Broeckhoven^1|9, E. Van Gansewinkel^5|10, J. De Bruijne², F. Eskens³, D. De Groot⁴, K. Hermans⁵, N. Mohammad⁶, F. Van Vilsteren⁷, C. Verslype⁸, W. Moris⁹, M. Roest¹⁰, B. De Laat¹⁰ , J. De Vos-Geelen⁵, M. Kramer^1|9 | ¹Department of Gastroenterology and Hepatology, GROW – Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; ²Department of Gastroenterology & Hepatology, Utrecht University, University Medical Center Utrecht, The Netherlands; ³Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands; ⁴Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, the Netherlands; ⁵Department of Internal Medicine, Division of Medical Oncology, GROW – Research Institute for Oncology & Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; ⁶Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands; ⁷Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands; ⁸Digestive Oncology, University Hospitals Leuven, Belgium; ⁹Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands; ¹⁰Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands, on behalf of the Dutch Hepatocellular & Cholangiocarcinoma Group

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.554

  103

  PDF: 19